TY - JOUR
T1 - Neuroendocrine tumors
T2 - Novel approaches in the age of targeted therapy
AU - Phan, Alexandria T.
AU - Yao, James C.
PY - 2008/12/1
Y1 - 2008/12/1
N2 - The diagnosed incidence rate of neuroendocrine tumors (NETs) is on the rise. Prevalence calculations show NETs to be more common then previously thought. Although generally thought to be indolent, advanced NETs remain incurable and are resistant to most cytotoxic agents. The available biologic agents have limited activity against these tumors. Novel and active agents are clearly needed. The recent emergence of molecularly targeted therapy in oncology has brought renewed interest in the development of novel agents for this group of diseases. This paper will review the molecular biology of NETs, promising novel targeted therapy approaches including agents targeting angiogenesis and mammalian target of rapamycin (mTOR) pathways, as well as pivotal phase III studies that may set new standards of care for this disease.
AB - The diagnosed incidence rate of neuroendocrine tumors (NETs) is on the rise. Prevalence calculations show NETs to be more common then previously thought. Although generally thought to be indolent, advanced NETs remain incurable and are resistant to most cytotoxic agents. The available biologic agents have limited activity against these tumors. Novel and active agents are clearly needed. The recent emergence of molecularly targeted therapy in oncology has brought renewed interest in the development of novel agents for this group of diseases. This paper will review the molecular biology of NETs, promising novel targeted therapy approaches including agents targeting angiogenesis and mammalian target of rapamycin (mTOR) pathways, as well as pivotal phase III studies that may set new standards of care for this disease.
UR - http://www.scopus.com/inward/record.url?scp=59349087915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59349087915&partnerID=8YFLogxK
M3 - Review article
C2 - 19198220
AN - SCOPUS:59349087915
VL - 22
SP - 1617
EP - 1623
JO - Oncology (Williston Park, N.Y.)
JF - Oncology (Williston Park, N.Y.)
SN - 0890-9091
IS - 14
ER -